Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

A new form of proton therapy designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects, is now being tested in a phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

September 11, 2026

Vol.52 No.33

Cancer Policy

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

The U.S. Senate has passed a stopgap spending bill that, in addition to avoiding a government shutdown at the end of September, would preclude the White House Office of Management and Budget from finalizing a proposal that seeks to fundamentally redraw the ground rules for all federally funded research (The Cancer Letter, Aug. 7, 2026).

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks.

August 14, 2026

Vol.52 No.32

Cancer Policy

HRSA redrafts 340B rebate pilot program after courts block the original version

After returning to the drawing board, the Health Resources and Services Administration has announced a second iteration of the 340B Rebate Model Pilot Program, after it withdrew the original pilot earlier this year.

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

The phase III XPORT-EC-042 trial, evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer, did not meet its primary endpoint of progression free survival.

August 07, 2026

Vol.52 No.31

Patient groups urge Congress to reauthorize Prescription Drug User Fee Act, improve clinical trial diversity

YOU MAY BE INTERESTED IN

Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC

Penn Medicine launches first human clinical trial to test precision form of FLASH proton therapy

Senate passes stopgap bill that would ban OMB from finalizing rule that would politicize science

SANRECO phase II study of divesiran in polycythemia vera meets primary endpoint

HRSA redrafts 340B rebate pilot program after courts block the original version

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

Renew today!

Subscriber content

Never miss an issue!

Login